Alcohol use disorder (AUD) is widespread and problematic in the United States, and current pharmacotherapy options have relatively modest effects. Therefore, novel interventions such as ketamine therapy have gained interest as potentially efficacious options, known to generate unique psychotherapeutic experiences. The present secondary analysis examines the acute subjective experiences—both quantitatively and qualitatively—of clinical trial participants with AUD who received intravenous (IV) ketamine therapy in the hospital setting.
Materials and Methods:
Among a subset of inpatient clinical trial participants with AUD who received IV ketamine therapy (n = 12), acceptability and tolerability were assessed. Next, a brief directed content analysis was performed, utilizing textual data transcribed immediately after ketamine infusion. Six preselected themes from the literature were chosen to apply to our text.
Results:
Among this sample, IV ketamine therapy appeared well tolerated and highly acceptable (mean 9.5 on 0–10 Likert scale). The mean Clinician-Administered Dissociative States Scale (CADSS) score was 21.7 (out of max 92). It seemed to occasion experiences that were largely positive, transporting, visual, and meaningful. The most frequently assigned themes in our data set were “Meaningful, spiritual, and mystical experiences,” “Positive affect,” and “Inherent contradictions of the acute experience.”
Conclusions:
Prior themes derived from two theory-generating publications applied widely to our participants' reported experiences. The hospital setting itself did not appear to be a barrier in facilitating these experiences.
WhiteAM, CastleIJP, PowellPA, et al.Alcohol-related deaths during the COVID-19 pandemic. JAMA, 2022; 327(17):1704–1706; doi: 10.1001/jama.2022.4308
4.
AntonRF, LathamP, VoroninK, et al.Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: A randomized clinical trial. JAMA Intern Med, 2020; 180(5):728; doi: 10.1001/jamainternmed.2020.0249
5.
SwiftRM, AstonER. Pharmacotherapy for alcohol use disorder: Current and emerging therapies. Harv Rev Psychiatry, 2015; 23(2):122–133; doi: 10.1097/HRP.0000000000000079
6.
CalabreseJ, BrownJ, HasanM, et al.Hospital readmission in alcohol use disorder patients: The role of anti-craving medications and discharge disposition. HCA Healthc J Med, 2022; 3(2):39–45; doi: 10.36518/2689-0216.1243
LevinC, IlgenM, MoosR. Avoidance coping strategies moderate the relationship between self-efficacy and 5-year alcohol treatment outcomes. Psychol Addict Behav, 2007; 21(1):108–113; doi: 10.1037/0893-164X.21.1.108
9.
ChurakovaI, BurlakaV, ParkerTW. Relationship between alcohol use, spirituality, and coping. Int J Ment Health Addict, 2017; 15(4):842–852; doi: 10.1007/s11469-017-9759-6
10.
BrysonCL, AuDH, SunH, et al.Alcohol screening scores and medication nonadherence. Ann Intern Med, 2008; 149(11):795–803; doi: 10.7326/0003-4819-149-11-200812020-00004
11.
DermodySS, WardellJD, StonerSA, et al.Predictors of daily adherence to naltrexone for alcohol use disorder treatment during a mobile health intervention. Ann Behav Med Publ Soc Behav Med, 2018; 52(9):787–797; doi: 10.1093/abm/kax053
12.
CollinsSE. Associations between socioeconomic factors and alcohol outcomes. Alcohol Res Curr Rev, 2016; 38(1):83–94.
13.
KatikireddiSV, WhitleyE, LewseyJ, et al.Socioeconomic status as an effect modifier of alcohol consumption and harm: Analysis of linked cohort data. Lancet Public Health, 2017; 2(6):e267–e276; doi: 10.1016/S2468-2667(17)30078-6
14.
O'DonnellKC, RobertsDE, ChingTHW, et al.What is in a name? The many meanings of “psychedelic.”. Psychedelic Med, 2023; 1(4):187–189; doi: 10.1089/psymed.2023.0011
15.
Garcia-RomeuA, GriffithsRR, JohnsonMW. Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction. Curr Drug Abuse Rev, 2014; 7(3):157–164.
16.
BogenschutzMP, ForcehimesAA, PommyJA, et al.Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol, 2015; 29(3):289–299; doi: 10.1177/0269881114565144
GarelN, McAnultyC, GreenwayKT, et al.Efficacy of ketamine intervention to decrease alcohol use, cravings, and withdrawal symptoms in adults with problematic alcohol use or alcohol use disorder: A systematic review and comprehensive analysis of mechanism of actions. Drug Alcohol Depend, 2022; 239:109606; doi: 10.1016/j.drugalcdep.2022.109606
19.
KelsonM, BurnettJM, MatthewsA, et al.Ketamine treatment for alcohol use disorder: A systematic review. Cureus, 15(5):e38498; doi: 10.7759/cureus.38498
20.
DasRK, GaleG, WalshK, et al.Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories. Nat Commun, 2019; 10(1):1–10; doi: 10.1038/s41467-019-13162-w
21.
DakwarE, LevinF, HartCL, et al.A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: A randomized midazolam-controlled pilot trial. Am J Psychiatry, 2020; 177(2):125–133; doi: 10.1176/appi.ajp.2019.19070684
22.
GrabskiM, McAndrewA, LawnW, et al.Adjunctive ketamine with relapse prevention–based psychological therapy in the treatment of alcohol use disorder. Am J Psychiatry, 2022; 179(2):152–162; doi: 10.1176/appi.ajp.2021.21030277
23.
MollaahmetogluOM, KeelerJ, AshbullbyKJ, et al.“This is something that changed my life”: A qualitative study of patients' experiences in a clinical trial of ketamine treatment for alcohol use disorders. Front Psychiatry, 2021; 12:695335; doi: 10.3389/fpsyt.2021.695335
24.
LuckenbaughDA, NiciuMJ, IonescuDF, et al.Do the dissociative side effects of ketamine mediate its antidepressant effects?. J Affect Disord, 2014; 159:56–61; doi: 10.1016/j.jad.2014.02.017
25.
MathaiDS, NayakSM, YadenDB, et al.Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine. Psychopharmacology (Berl), 2023; 240(4):827–836; doi: 10.1007/s00213-023-06324-8
26.
Ivan Ezquerra-RomanoI, LawnW, KrupitskyE, et al.Ketamine for the treatment of addiction: Evidence and potential mechanisms. Neuropharmacology, 2018; 142:72–82; doi: 10.1016/j.neuropharm.2018.01.017
27.
MathaiDS, MeyerMJ, StorchEA, et al.The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. J Affect Disord, 2020; 264:123–129; doi: 10.1016/j.jad.2019.12.023
28.
HackLM, ZhangX, HeifetsBD, et al.Ketamine's acute effects on negative brain states are mediated through distinct altered states of consciousness in humans. Nat Commun, 2023; 14(1):6631; doi: 10.1038/s41467-023-42141-5
29.
LiiTR, SmithAE, FlohrJR, et al.Randomized trial of ketamine masked by surgical anesthesia in patients with depression. Nat Ment Health, 2023; 1(11):876–886; doi: 10.1038/s44220-023-00140-x
30.
RothbergRL, AzhariN, HaugNA, et al.Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial. J Psychopharmacol, 2021; 35(2):150–158; doi: 10.1177/0269881120970879
31.
BraunV, ClarkeV. Conceptual and design thinking for thematic analysis. Qual Psychol, 2022; 9(1):3–26; doi: 10.1037/qup0000196
32.
TerasakiD, LohR, CornellA, et al.Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: Pilot trial feasibility and readmission rates. Addict Sci Clin Pract, 2022; 17(1):64; doi: 10.1186/s13722-022-00345-y
EnglanderH, DobbertinK, LindBK, et al.Inpatient addiction medicine consultation and post-hospital substance use disorder treatment engagement: A propensity-matched analysis. J Gen Intern Med, 2019; 34(12):2796–2803; doi: 10.1007/s11606-019-05251-9
35.
TerasakiD, HanrattyR, ThurstoneC. More than MAT: Lesser-known benefits of an inpatient addiction consult service. Hosp Pract (1995), 2023; 51(3):107–109; doi: 10.1080/21548331.2023.2225977
36.
HasinDS, O'BrienCP, AuriacombeM, et al.DSM-5 criteria for substance use disorders: Recommendations and Rationale. Am J Psychiatry, 2013; 170(8):834–851; doi: 10.1176/appi.ajp.2013.12060782
HarrisPA, TaylorR, MinorBL, et al.The REDCap consortium: Building an international community of software platform partners. J Biomed Inform, 2019; 95:103208; doi: 10.1016/j.jbi.2019.103208
39.
KroenkeK, SpitzerRL, WilliamsJBW. The PHQ-9. J Gen Intern Med, 2001; 16(9):606–613; doi: 10.1046/j.1525-1497.2001.016009606.x
40.
BremnerJD, KrystalJH, PutnamFW, et al.Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress, 1998; 11(1):125–136; doi: 10.1023/A:1024465317902
HsiehHF, ShannonSE. Three approaches to qualitative content analysis. Qual Health Res, 2005; 15(9):1277–1288; doi: 10.1177/1049732305276687
43.
HoodRW. The construction and preliminary validation of a measure of reported mystical experience. J Sci Study Relig, 1975; 14(1):29–41; doi: 10.2307/1384454
NelsonAC, KehoeJ, SankoffJ, et al.Benzodiazepines vs barbiturates for alcohol withdrawal: Analysis of 3 different treatment protocols. Am J Emerg Med, 2019; 37(4):733–736; doi: 10.1016/j.ajem.2019.01.002
48.
JesseS, BråthenG, FerraraM, et al.Alcohol withdrawal syndrome: Mechanisms, manifestations, and management. Acta Neurol Scand, 2017; 135(1):4–16; doi: 10.1111/ane.12671
49.
HooverK, LockhartS, CallisterC, et al.Experiences of stigma in hospitals with addiction consultation services: A qualitative analysis of patients' and hospital-based providers' perspectives. J Subst Abuse Treat, 2022; 138:108708; doi: 10.1016/j.jsat.2021.108708
50.
KrystalJH, PetrakisIL, LimoncelliD, et al.Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients. Neuropsychopharmacology, 2003; 28(11):2020–2028; doi: 10.1038/sj.npp.1300252
51.
PetrakisIL, LimoncelliD, GueorguievaR, et al.Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism. Am J Psychiatry, 2004; 161(10):1776–1782; doi: 10.1176/ajp.161.10.1776
52.
O'CathainA, ThomasKJ. “Any other comments?” Open questions on questionnaires—A bane or a bonus to research?. BMC Med Res Methodol, 2004; 4(1):25; doi: 10.1186/1471-2288-4-25
